CYPRESS BIOSCIENCE INC

Cypress Bioscience Inc. is a small-cap developer within the Biological Products (No Diagnostic Substances) space, deriving its identity from SIC 2836-style therapeutic innovations and the preparation of targeted compound libraries for cardiometabolic and CNS disorders. Its core products remain investigational oral therapies and proprietary delivery technologies aimed at pharmaceutical partners, specialist physicians and hospital systems that demand novel treatments to address unmet needs. The company also offers early-stage research tools and regulatory support services to accelerate IND filings. In this highly regulated arena the Federal Food, Drug, and Cosmetic Act oversees clinical trials, manufacturing and labeling, while post-marketing surveillance and patent litigation pressures constitute material risks to commercialization plans and cash burn, all compounded by the absence of recurring revenue until approvals arrive. With its latest filing being the Form 10-Q from November 1999, Cypress continues to report through the historical framework captured on the SEC’s site under CIK 716054, so view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025